Ingevity increases caprolactone monomer capacity at its Warrington, UK facility

Ingevity Corporation (NYSE:NGVT) today announced that it will increase caprolactone monomer capacity at its facility in Warrington, U.K., through a series of optimization projects over the next 12 months that are expected to increase Ingevitys global monomer production capacity by over 20% and position the company to better meet demand and more effectively serve customers.